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Abstract
Background: Amyloid-β (Aβ)-stimulated microglial inflammatory responses engage mitogen-activated protein
kinase (MAPK) pathways in Alzheimer’s disease (AD). Mixed-lineage kinases (MLKs) regulate upstream MAPK
signaling that include p38 MAPK and c-Jun amino-terminal kinase (JNK). However, whether MLK-MAPK pathways
affect Aβ-mediated neuroinflammation is unknown. To this end, we investigated if URMC-099, a brain-penetrant
small-molecule MLK type 3 inhibitor, can modulate Aβ trafficking and processing required for generating
AD-associated microglial inflammatory responses.
Methods: Aβ1-42 (Aβ42) and/or URMC-099-treated murine microglia were investigated for phosphorylated
mitogen-activated protein kinase kinase (MKK)3, MKK4 (p-MKK3, p-MKK4), p38 (p-p38), and JNK (p-JNK). These
pathways were studied in tandem with the expression of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6,
and tumor necrosis factor (TNF)-α. Gene expression of the anti-inflammatory cytokines, IL-4 and IL-13, was evaluated
by real-time quantitative polymerase chain reaction. Aβ uptake and expression of scavenger receptors were
measured. Protein trafficking was assessed by measures of endolysosomal markers using confocal microscopy.
Results: Aβ42-mediated microglial activation pathways were shown by phosphorylation of MKK3, MKK4, p38, and
JNK and by expression of IL-1β, IL-6, and TNF-α. URMC-099 modulated microglial inflammatory responses with
induction of IL-4 and IL-13. Phagocytosis of Aβ42 was facilitated by URMC-099 with up-regulation of scavenger
receptors. Co-localization of Aβ and endolysosomal markers associated with enhanced Aβ42 degradation was
observed.
Conclusions: URMC-099 reduced microglial inflammatory responses and facilitated phagolysosomal trafficking with
associated Aβ degradation. These data demonstrate a new immunomodulatory role for URMC-099 to inhibit MLK
and to induce microglial anti-inflammatory responses. Thus, URMC-099 may be developed further as a novel
disease-modifying AD therapy.
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Background
Neuroinflammation is a pathogenic driver for Alzheimer’s
disease (AD) [1–3]. Amyloid-β (Aβ)-activated microglia
secrete pro-inflammatory neurotoxins that are strongly
linked to AD-associated neural injury. Such inflamma-
tory responses are notably tied beyond AD to common
age-related neurodegenerative, neuroinfectious, and
neuroinflammatory disorders [4–13]. Activated micro-
glia, in turn, stimulate neurons to produce more Aβ and
the microtubule-associated protein tau, in a vicious para-
crine loop [14]. The events change the brain’s microenvir-
onment and further affect microglial activation, leading to
progressive neuronal injuries. The end result is a paracrine
feedback of neurotoxin amplification that drives disease
with Aβ serving as the principal inducer of innate immune
activation [15–17]. This has led many researchers to
develop the means to harness immunity for therapeutic
gain. Notably, Aβ vaccination can effectively clear Aβ in
both mouse models of human disease and AD patients
[18, 19]. For treatment of AD, Aβ immunization reduces
the Aβ42 load with immunomodulation, including micro-
glial phagocytosis and changed lysosomal and scavenger
markers [20, 21]. However, such immunizations can also
result in the development of meningoencephalitis (~6 %)
[22], spongiosis, and neuronal loss [23]. Since removal of
plaques at later stages of disease marked by neurofibrillary
tangle formation was not proven to be beneficial, alterna-
tive treatment strategies are likely required. These might
improve clinical outcomes if administered years before
clinical signs and symptoms emerge. Indeed, such a
therapeutic approach could speed clearance of Aβ and
modify inflammatory activities before disease develops.
Prior therapeutic approaches focused on develop-
ment of immunomodulatory agents that affect AD
microglial responses. For example, nonsteroidal anti-
inflammatory drugs (NSAIDs) or antioxidants reduce
harmful microglial inflammatory activities and protect
neurons in animal models of human disease [24, 25].
While the drugs are effective in converting microglial
polarization from an M1 (classical activation) to an M2
(alternative activation) phenotype and attenuating neuro-
toxin production, successful human therapeutic transla-
tion remains out of reach [1, 25, 26].
While the “selectively non-selective” brain-penetrant
mixed-lineage kinase type 3 (MLK3) inhibitor, URMC-
099, can attenuate neuroinflammatory responses and
facilitate the actions of long-acting nanoformulated anti-
retroviral drugs during human immunodeficiency virus-
1 (HIV-1) infection [27–29], it is not known whether it
could also harness autophagy. If operative, this could
occur as a secondary response to phagocytosis of Aβ. Here,
we show yet another novel therapeutic role of URMC-099
as an immune modulator in microglial inflammation and
phagocytosis through accelerating phagolysosomal pathway
Aβ degradation. In this manner, we posit that the drug
could be developed as a novel AD therapeutic candidate.
Methods
Microglia isolation and cultivation
Housing, care, and breeding of non-transgenic mice
(B6.129 hybrid background) were approved by the
Institutional Animal Care and Use Committee of the
University of Nebraska Medical Center. Primary cultured
mouse microglia were prepared from the postnatal day 1
newborn mouse brains [30–32]. Meninges-free newborn
mouse cortices were minced and trypsinized, followed by
mechanical dissociation and filtration to remove tissue
chunks. Cells were plated onto plastic tissue culture
bottles as mixed glial cultures in Dulbecco’s modified
eagle medium supplemented with heat-inactivated 10 %
fetal bovine serum, 50 μg/ml penicillin/streptomycin (Life
Technologies, Carlsbad, CA, USA) and macrophage
colony-stimulating factor (MCSF). Microglia were released
from astrocytes in the tissue culture media by shaking.
Non-adherent cells were collected 7–14 days after plating.
Aβ activation and URMC-099 treatment
Microglia were plated at a density of 2 × 105 onto 24-well
plates for RNA/protein extraction or onto 24-well plates
with glass coverslips for confocal microscopy. 2 × 104 cells
were placed in each 96-well plate for immunofluorescence
studies. One day before Aβ exposure and URMC-099
treatment, media was replaced without MCSF. Microglia
were pre-incubated for 30 min with URMC-099 (100 nM)
[28]. Notably, URMC-099 administered at 100 nM did
not affect microglial viability as measured by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay (Additional file 1: Figure S1) that was per-
formed as previously described [33]. After pre-incubation
with URMC-099, microglia were incubated with media
containing the monomeric Aβ42 (10 μM, Life Technolo-
gies, Carlsbad, CA, USA) prepared as previously described
[32]. Since monomeric rather than oligomeric Aβ1-42
(Aβ42) peptides are effectively phagocytosed by human
monocyte-derived macrophages [34], monomeric Aβ42
was used. After Aβ treatment, microglia were harvested
for total RNA or protein extraction or fixed with
freshly depolymerized 4 % paraformaldehyde (PFA) in
PBS for 15 min for immunofluorescence assays.
Immunoblot and ELISA tests
Microglial cells were harvested using ice-cold RIPA buffer
with protease and phosphatase inhibitor cocktail at end
points and centrifuged at 15,000xg for 10 min at 4 °C to
collect cell lysates. Protein concentrations were determined
using a Micro BCA Protein Assay (Thermo Fisher
Scientific, Waltham, MA, USA). For immunoblots, protein
lysates were diluted 1:1 with Laemmli buffer containing
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β-mercaptoethanol, incubated at 100 °C for 5 min, electro-
phoresed on sodium dodecyl sulfate-polyacrylamide gels,
and electroblotted to 0.45-μm pore size polyvinylidene
fluoride membranes (Immobilon-P, Millipore, Billerica,
MA, USA). Membranes were blocked in 3 % bovine serum
albumin/TBST or 5 % skim milk/TBST and incubated with
antibodies (Abs) to phospho-MKK3 (p-MKK3), total
MKK3, phospho-MKK4 (p-MKK4), total MKK4, phospho-
p38 (p-p38), total p38, phosphor-JNK (p-JNK), total JNK
(1:1000, Cell Signaling Technology, Danvers, MA), CD36,
CD47 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and Aβ (6E10, 1:1000, Covance, Emeryville, CA,
USA), at 4 °C for overnight, followed by 30-min incubation
in 3 % bovine serum albumin/TBST or 5 % skim milk/
TBST with HRP-conjugated anti-goat, mouse, or rabbit
IgG Abs (1:2000, Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Immunoreactive bands were detected with
SuperSignal West Pico or Femto Chemiluminescent
substrate and captured using a myECL Imager (Thermo
Fisher Scientific, Waltham, MA, USA). After detection
of the bands, membranes were incubated with Restore
Western Blot Stripping Buffer (Thermo Fisher Scien-
tific, Waltham, MA, USA) and were then used to de-
tect β-actin for normalization using HRP-conjugated
anti-β-actin monoclonal (Sigma, St. Louis, MO, USA). For
quantitative analysis, ImageJ software (NIH, Bethesda,
MD, USA) was used to quantify band intensities relative
to total proteins or control β-actin expression. For ELISA,
tissue culture media were subjected to capture antibodies
for IL-1β, IL-6, and TNF-α (PeproTech, Rocky Hill, NJ,
USA) according to the manufacturer’s instructions. For
Aβ42 ELISA, cell lysates and tissue culture media were
subjected to Aβ42 ELISA (Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Immunofluorescence and confocal microscopy
Immunofluorescence was performed using pan-Aβ Ab
(rabbit polyclonal, 1:100) and Alexa Fluor®488-conjugated
anti-rabbit IgG (1:1000), followed by 30 min counterstain-
ing with 4′,6-diamino-2-phenyl-indole (DAPI) (all from
Life Technologies, Carlsbad, CA, USA). Images were
captured using DP Controller and DP Manager with a
DP71 digital camera (Olympus, Orangeburg, NY, USA)
attached to a Nikon Eclipse TE300 inverted microscope
(Nikon, Melville, NY, USA). For confocal microscopy, PFA-
fixed microglia were immunostained with Abs to Aβ (6E10,
1:1000, Covance, Emeryville, CA, USA), Rab5, Rab7 (rabbit
polyclonal, 1:500, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), and Lamp1 (rabbit polyclonal, ab24170, 1:500,
Abcam, Cambridge, MA, USA). Alexa Fluor 488 goat anti-
mouse IgG and Alexa Fluor 568 goat anti-rabbit IgG were
used as secondary, followed by 30-min counterstaining with
DAPI (Life Technologies, Carlsbad, CA, USA). Images were
captured using a 63X oil lens on a LSM 710 confocal
microscope (Carl Zeiss Microimaging Inc., Thornwood,
NY, USA). Images were quantified using ImageJ software
with a co-localization plugin (https://imagej.nih.gov/ij/
plugins/colocalization.html) (NIH, Bethesda, MD, USA).
RNA extraction and transcript analyses
Total RNA was extracted from microglia using TRIzol
(Life Technologies, Carlsbad, CA, USA). For PCR-based
gene expression analyses, cDNA was synthesized with
1 μg of total RNA as a template using a Verso cDNA
synthesis kit (Thermo Fisher Scientific, Waltham, MA,
USA), and quantitative real-time RT-PCR (RT2-qPCR)
was performed on a thermocycler (Mastercycler Gradi-
ent, Eppendorf Scientific Inc., Westbury, NY, USA) using
2x SYBR Green qPCR Master Mix (Biotool.com, Hous-
ton, TX, USA) and gene specific primer sets (Table 1).
All primer sequences were obtained from PrimerBank
(https://pga.mgh.harvard.edu/primerbank/) [35]. Ther-
mal cycler conditions were as follows: 10 min at 95 °C
for activation of polymerase, followed by 40 cycles of a
two-step PCR (95 °C for 15 s and 60 °C for 1 min). Rela-
tive expression for target genes was determined by the
ΔΔCt method and normalized with glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) gene expression as an
internal control. Each ΔCt value was determined by sub-
tracting Gapdh Ct value from the target gene Ct value.
The ΔΔCt was calculated by subtracting the ΔCt value of
the control from the ΔCt value of other groups. 2−ΔΔCt
represented the average relative amount of mRNA to
control for each target gene.
Statistical analyses
All data were normally distributed and presented as
mean values ± standard errors of the mean (SEM). In the
case of single mean comparison, data were analyzed by
Student’s t test. In case of multiple mean comparisons,
the data were analyzed by one-way ANOVA. When
there were significant differences between ≥3 sample
means, post hoc comparisons with the Newman–Keuls
method was performed using statistics software (Prism
4.0, Graphpad Software, San Diego, CA, USA). A value
of p < 0.05 was regarded as a significant difference.
Table 1 Primers for qPCR analysis
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Results
URMC-099 inhibits microglial p38 and JNK MAPK
signaling cascades
Aβ activates p38 and JNK MAPK cascades to produce
pro-inflammatory mediators in microglia [36–38], and
has previously been shown to activate MLK3 in cortical
neurons [39], but not microglia. Thus, we tested whether
URMC-099 could affect the MAPK cascades in Aβ42-
stimulated microglia (Fig. 1). As MKK3/6 and MKK4/7
regulate p38 and JNK phosphorylation downstream
MLK3 [40], we examined the phosphorylation patterns
of MKK3 and MKK4 (Fig. 1a, c). A 30-min Aβ42
treatment increased MKK3 phosphorylation 32.1 % as
compared to untreated controls (Fig. 1b). Moreover,
trends in MKK4 phosphorylation were also seen with an
8.0 % increase when compared to untreated controls
(Fig. 1d). However, URMC-099 treatment significantly
reduced both MKK3 and MKK4 phosphorylation in the
Aβ-stimulated microglia with decreases of 26.9 and
20.5 % in MKK3 and MKK4 phosphorylation, respect-
ively (Fig. 1b, d). The phosphorylation of p38 and p46/
p54-JNK downstream MKK3 and MKK4 was also
assayed (Fig. 1e, g). While a 30-min exposure to Aβ42
showed a rapid induction of both p38 and p46/p54-JNK
phosphorylation (increases of 84.8, 18.7, and 25.1 % in
p38, p46-JNK, and p54-JNK, respectively, as compared
to untreated controls, Fig. 1f, h, i), URMC-099 treatment
resulted in significant reduction in p38 and JNK
phosphorylation in the Aβ-stimulated microglia. Here,
decreases were seen at 21.5, 17.3, and 23.7 % in p38,
p46-JNK, and p54-JNK, respectively (Fig. 1f, h, i). To as-
sess the effects of URMC-099 on Aβ42-mediated micro-
glial cytotoxicity, we measured cell viability using the
MTT assay. Aβ42-treatment reduced cell viability
(Additional file 2: Figure S2) as observed previously
[31]. Although URMC-099 treatment did not amelior-
ate Aβ42-mediated cytotoxicity, trends in protection of
cell viability were observed with 9.4 and 16.0 % in-
crease in 3- and 48-h incubation, respectively, when
compared to Aβ42 treatment (Additional file 2: Figure
S2). These results support the notion that URMC-099
inhibits MLK3-MKK3/4-mediated activation of p38
and JNK MAPK cascades in Aβ-activated microglia.
URMC-099 inhibits activated microglial pro-inflammatory
cytokines
URMC-099 exerts anti-inflammatory effects on microglia
exposed to the HIV-1 Tat [28]. To determine whether
URMC-099 has similar effects for β-amyloidosis, cultured
murine microglia were treated with URMC-099 and
exposed to soluble Aβ42 for 30 min. While Aβ42 stimula-
tion induced IL-1β, IL-6, and TNF-α gene expression,
URMC-099 reversed this induction (decreases of 84.8,
85.9, and 97.4 % to Aβ42 stimulation for IL-1β, IL-6,
and TNF-α, respectively, Fig. 2a). The qPCR results
were validated by measuring protein production of pro-
Fig. 1 URMC-099 inhibits p38 and JNK MAPK signaling cascades in Aβ-stimulated microglia. Immunoblots of p-MKK3 and total MKK3 (a), p-MKK4
(asterisk; non-specific bands) and total MKK4 (c), p-p38 and total p38 (e), p-JNK p54 (top), p46 (bottom), and total JNK (g). Quantification of
p-MKK3 (b), p-MKK4 (d) p-p38 (f), p-JNK p54 (h), and p46 (i) levels. Data are presented as mean ± SEM, a,c,dp < 0.05, aa,cc,ddp < 0.01, a vs control,
cvs URMC-099, dvs Aβ + URMC-099, one-way ANOVA, Newman–Keuls post hoc test
Dong et al. Journal of Neuroinflammation  (2016) 13:184 Page 4 of 11
inflammatory cytokines in media. After 48-h Aβ42 stimu-
lation, URMC-099 treatment inhibited IL-1β, IL-6, and
TNF-α (decreases of 62.3, 99.8, and 99.9 % to Aβ42 stimu-
lation for IL-1β, IL-6, and TNF-α, respectively, Fig. 2b).
These data strongly support the anti-inflammatory effects
of URMC-099 on Aβ-stimulated microglia.
Anti-inflammatory effects of URMC-099 in
Aβ42-stimulated microglia
To determine the neuroinflammatory phenotype in
URMC-099-treated microglia, total RNA was isolated
and RT2-qPCR was performed for genes specific to
IL-4 and IL-13. Data were shown as fold change com-
pared to control (Fig. 3). While 30-min Aβ42 stimula-
tion did not alter gene expression of IL-4 and IL-13,
URMC-099 significantly induced this expression
pattern (increases of 111.1 and 345.7 % in IL-4 and
IL-13, respectively, Fig. 3), further supporting the
anti-inflammatory effects of URMC-099 on Aβ-
stimulated microglia.
URMC-099 facilitates microglial Aβ uptake
Since URMC-099 has anti-inflammatory effects in
Aβ-stimulated microglia, we hypothesized that co-
temporaneous administration of URMC-099 to micro-
glia could accelerate Aβ phagocytosis and subsequent
degradation [41–44]. To this end, we tested if URMC-
099 could facilitate Aβ42 internalization. URMC-099-
treated microglia were incubated with Aβ42 for 30 min,
then immunostained using pan-Aβ primary and Alexa
488-secondary antibodies (Fig. 4a). Quantification of
immunofluorescent intensity showed that relative im-
munofluorescence was increased in URMC-099-treated
microglia, as compared to Aβ42 treatment only (76.9 %
increase, Fig. 4b), suggesting that URMC-099 promotes
Aβ phagocytosis.
Fig. 2 URMC-099 inhibits Aβ-activated microglial pro-inflammatory cytokines. a A conventional RT2-qPCR was performed to measure IL-1β, IL-6,
or TNF-α expression using primer sets (Table 1) and synthesized cDNA with total RNA isolated from murine microglia (n = 3 per group).
b Quantification of IL-1β, IL-6, or TNF-α protein secretion from murine microglia (n = 3 per group). Data are presented as mean ± SEM, a,c,dp < 0.05,
aa,cc,ddp < 0.01, aaap < 0.001, avs control, cvs URMC-099, dvs Aβ + URMC-099, one-way ANOVA, Newman–Keuls post hoc test
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URMC-099 alters scavenger receptor expression in
microglia
A previous study demonstrated that microglial phago-
cytic capacity is linked to scavenger receptor (SR)
expression levels in microglia in AD mouse models [45].
To pursue the mechanism of how URMC-099 facilitates
Aβ phagocytosis, we examined the expression of SRs.
CD36 and CD47 expression was assessed by immuno-
blotting (Fig. 5a). CD36 expression was increased in all
treated groups (increases of 44.4, 56.1, and 44.1 % in
URMC-099 only, Aβ only, and Aβ plus URMC-099 to
control, respectively, Fig. 5b), while CD47 expression
was significantly increased with URMC-099 treatment
(increases of 55.9 and 50.2 % in URMC-099 only and Aβ
plus URMC-099 to control, respectively, Fig. 5b), demon-
strating URMC-099-specific alteration in SR expression.
URMC-099 increases Aβ co-localization with Rab7 and
Lamp1
In response to Aβ binding to SRs, microglia start to
engulf Aβ by phagocytosis, and then Aβ enters into the
endolysosomal pathway. Thus, we investigated how
URMC-099 affects the endolysosomal trafficking under-
lying Aβ phagocytosis. Microglia treated as described
above were immunostained with antibodies to Rab7
(for late endosomes, Fig. 6a) and Lamp1 (for lysosomes,
Fig. 6c) at 1-h post-incubation with Aβ. Confocal micros-
copy demonstrated that co-localization of Rab7 and
Lamp1 with Aβ42 was increased in URMC-099-treated
microglia, compared to untreated microglia (21.2 and
26.3 % increases in Rab7 and Lamp1, respectively,
Fig. 6c, d). To investigate Aβ metabolism, microglia
were exposed to Aβ42 for 30 min, washed and cultured in
fresh media for additional 1 h, then harvested for
immunoblotting (Fig. 7a). Co-treatment with URMC-099
significantly reduced immunoreactivity of monomeric,
dimeric, and high molecular weight (HMW) Aβ42, as
compared to Aβ42 treatment only (39.3, 30.6, and 42.3 %
decreases in monomeric, dimeric, and HMW Aβ42,
respectively, Fig. 7b). To validate these results, microglia
were exposed to Aβ42 for 30 min, followed by wash and
culture in fresh media for additional 1 h, and then Aβ42
release and retention in microglia were quantified using
ELISA. While URMC-099 had no effect on Aβ42 release
(Fig. 7c), co-treatment with URMC-099 significantly
reduced Aβ42 with a 50.2 % reduction (Fig. 7d).
These data suggest that URMC-099 promotes micro-
glial endolysosome-mediated degradation.
Discussion
Microglia are the resident immune cells that serve as the
first line of immune defense against invading pathogens
in the CNS. The immune response is accelerated by the
cell’s abilities to recognize pathogen-associated microbial
Fig. 3 URMC-099 induces gene expression of anti-inflammatory cytokines
in Aβ42-stimulated microglia. A conventional RT2-qPCR was performed to
measure IL-4 and IL-13 expression using primer sets (Table 1) and synthe-
sized cDNA with total RNA isolated from murine microglia (n= 3 per
group). Data are presented as mean± SEM, a,bp< 0.05, avs control,
bvs Aβ, one-way ANOVA, Newman–Keuls post hoc test
Fig. 4 URMC-099 facilitates microglial Aβ-uptake. a Primary mouse
microglia were incubated with soluble Aβ42 for 30 min, followed
by immunofluorescence with anti-Aβ Ab (green) and DAPI (blue)
for nuclear staining (blue). Merged captured images were shown.
Scale bar, 100 μm. b Dense intensity of Aβ42 fluorescence was
measured using ImageJ. Bars represent mean ± SEM. **p < 0.01
by Student’s t test
Dong et al. Journal of Neuroinflammation  (2016) 13:184 Page 6 of 11
Fig. 5 URMC-099 alters scavenger receptor expression in microglia. a Representative images of immunoblots for CD36 and CD47 in mouse
microglia after a 30-min Aβ42 stimulation. b Quantification CD36 and CD47 expression. Bars represent mean ± SEM. aa,ccp < 0.01, cccp < 0.001,
avs control, cvs Aβ, one-way ANOVA, Newman–Keuls post hoc test
Fig. 6 URMC-099 facilitates subcellular co-localization of Aβ42 with Rab7 and Lamp1 in murine microglia. Confocal microscopy shows cellular
localization of Rab7 late endosomal component (a, red) or Lamp1 lysosomal compartment (b, red) and Aβ42 (green). Merged images of Rab7
and Lamp1 are shown. Aβ42 co-localization with Rab7 (c) or Lamp1 (d) was quantified by ImageJ with a co-localization plugin. Scale bar = 50 μm.
Bars represent mean ± SEM. *p < 0.05 by Student’s t test
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patterns, induce key co-stimulatory molecules, and
secrete cytokines that facilitate induction of the adaptive
immune response in disease [46–48]. A principal micro-
glial function is to act as scavenger cells to first phago-
cytose then clear substances such as Aβ [48–50]. Notably,
Aβ is considered to be the initiating factor in AD inducing
neuroinflammation, subsequent synaptic and axonal inju-
ries, tau hyperphosphorylation, and ultimately neuronal
death [15–17, 51]. With these in mind, a number of
therapeutic strategies have been developed for facilitating
Aβ removal with the goal of improving disease outcomes.
Indeed, anti-inflammatory drugs, amyloid degradation
enzymes, and active/passive immunizations have been
evaluated as treatment approaches [52–55]. In particular,
NSAIDs and antioxidants are effective not only in
attenuating the neurotoxins secreted by Aβ-stimulated
microglia but also in facilitating microglial phagocytic
activity for Aβ clearance in animal models of human
disease [1, 25, 26]. To date, there has been no clear valid-
ation of any of these approaches for disease-modifying
outcomes in patients with AD, thus further studies for
alternative disease-modifying strategies are warranted.
Hence, we investigated whether URMC-099 could ameli-
orate Aβ-mediated microglial activation.
URMC-099 was discovered as a result of a large scree-
ning for MLK3 inhibitors structurally containing a pyr-
rolopyridine scaffold with an aryl piperazine side chain
[28, 29]; it can modify the production of pro-inflammatory
mediators by inhibiting MAPK signaling cascades
[36–38]. MLKs are MAPK kinase kinases (MAPKKKs)
that function as bonafide serine/threonine kinases,
although their catalytic domains have features of both
serine/threonine and tyrosine kinases. MLKs regulate
the p38/JNK signaling cascades that coordinate and
orchestrate numerous immune processes [40]. URMC-
099 is an inhibitor specific to MLK3 [28, 29] that is one of
the most widely expressed members of the MLK family
[56]. MLK3 is expressed in immune effector cells inclu-
ding microglia in the CNS and is activated by cellular and
metabolic stress [28, 57–60]. Based on these findings, we
posit that URMC-099 is a potential candidate for AD
therapeutics. Although it was previously unclear whether
Aβ induces classical microglial activation through MLK-
MAPK pathways, we showed that URMC-099 reduces
phosphorylation of MKK3/MKK4 and p38/JNK and
partially protected Aβ-mediated microglial cytotoxicity,
suggesting its therapeutic effect targeting MLK-MKK-
MAPK pathways in Aβ-mediated neuroinflammation in
microglia.
In AD, microglia contribute to tissue injury through
eliciting neuroinflammation and changing the CNS micro-
environment. Like peripheral macrophages, microglia
can be polarized into M1 and M2 phenotypes based
on their functional properties [25, 26, 61–63]. Aβ activa-
tion of microglia is associated with production of
pro-inflammatory cytokines (IL-1β/IL-6/TNF-α), traits
associated closely with the M1 phenotype [7, 8, 11, 25, 47,
64]. Alternatively, polarization to an M2 phenotype can
initiate an anti-inflammatory and repair phase [1, 25, 26].
The normal homeostatic balance between M1 and M2
phenotypes seems to be disturbed during disease progres-
sion in AD with the presence of more M1 microglia
appearing coincident with aging and disease [26]. Herein,
URMC-099 treatment was shown to inhibit IL-1β/IL-6/
TNF-α expression and coordinate with the up-regulation
of IL-4 and IL-13 genes. These data suggest that URMC-
099 treatment may initiate phenotypic changes by
inducing anti-inflammatory cytokines, thus has neuro-
protective activities [42–44].
Fig. 7 URMC-099 facilitates Aβ42 degradation in murine microglia.
a Microglia were exposed to Aβ42 for 30 min, followed by wash and
culture in fresh media for additional 1 h, and harvested for immunoblot
using a 10 % SDS-polyacrylamide Tris-Tricine gel and 6E10 antibody.
1-mer, monomeric Aβ42. 2-mer, dimeric Aβ42. Asterisk indicates high
molecular weight (HMW) Aβ42. b Band luminescent intensities for
monomeric, dimeric, and HMW Aβ42 were quantified by ImageJ
software. The amounts of Aβ42 in culture media (c) and microglial cell
lysates (d) were measured by human Aβ42-specific ELISA. Bars represent
mean ± SEM. (n= 3 per group). *p< 0.05 vs Aβ, as determined by
Student’s t test
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Additionally, microglia in the M2 phase speed Aβ
phagocytosis and degradation without neurotoxin pro-
duction [41–44]. An increase in phagocytosis of Aβ was
observed with URMC-099 treatment. Microglial phago-
cytic capacity is linked to SR expression levels [45].
CD36 is one of the SRs for Aβ and regulates Aβ clear-
ance as well as brain inflammation [65]. While Aβ ex-
posure increased CD36 expression similar to a previous
study with BV-2 microglia [66], co-administration of
URMC-099 with Aβ failed to reverse this up-regulation.
In contrast, URMC-099 increases CD47 expression in
microglia both alone and with Aβ. Since CD47 is an
integrin-associated transmembrane protein and partici-
pates in Aβ uptake and microglial pro-inflammatory
responses by forming the receptor complex CD36/
CD47/α6β1 integrin, which in turn stimulates microglial
phagocytic activity [67–69]. By increasing CD47 activity,
our results suggest that URMC-099 facilitates CD36/
CD47/α6β1-integrin-mediated microglial phagocytic
activity of Aβ. Moreover, URMC-099 facilitates co-
localization of Rab7 and Lamp1 with Aβ42, which may
promote endolysosomal-mediated Aβ degradation and
metabolism. Our data in aggregate suggests that these
pathologic events can be altered with the challenge of
how and when to optimally use disease-modifying agents
such as URMC-099 to restore homeostasis to the brain’s
microenvironment.
Conclusions
URMC-099 inhibits Aβ-mediated phosphorylation of
MKK3/4-p38/JNK and pro-inflammatory responses, and
up-regulates phagolysosomal trafficking and degradation
of Aβ. Such inhibition of phosphorylation by URMC-099
correlates with inhibition of microglial activation. URMC-
099 serves as an immune modulatory and neuroprotective
agent that may be developed to combat AD.
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mean ± SEM. (TIF 1588 kb)
Additional file 2: Figure S2. MTT assay of microglia treated with Aβ42
and URMC-099. Data are presented as mean ± SEM. (TIF 613 kb)
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